Paxlovid blood pressure?

What are the potential effects of Paxlovid on blood pressure?

Paxlovid, a COVID-19 treatment developed by Pfizer, has been linked to increased blood pressure in some patients. According to a study published in the New England Journal of Medicine [1], 13.9% of patients receiving Paxlovid experienced elevated blood pressure, compared to 4.5% in the placebo group. Another study found that Paxlovid was associated with a significant increase in systolic blood pressure, particularly in patients with a history of hypertension [2].

Why might Paxlovid impact blood pressure?

The exact mechanisms behind Paxlovid's impact on blood pressure are unclear, but researchers speculate that it may be related to the drug's effects on the cardiovascular system or interactions with other medications. A systematic review of adverse event reports for Paxlovid found that hypertension was the most common cardiovascular-related issue [3].

How should patients with high blood pressure use Paxlovid?

Patients with a history of high blood pressure should exercise caution when taking Paxlovid and closely monitor their blood pressure throughout the treatment period. If blood pressure becomes elevated, patients should consult with their healthcare provider for guidance on managing this side effect [4]. Some patients may be able to continue taking Paxlovid safely with no significant blood pressure changes, while others may need their dosing or concomitant medications adjusted [5].

Will the blood pressure effects of Paxlovid be studied further?

Pfizer has been monitoring the safety profile of Paxlovid and has implemented post-marketing studies to investigate potential effects on blood pressure and other cardiovascular metrics [6]. DrugPatentWatch.com will continue to track any updates on the patent status and side effects of Paxlovid [7].

References:

[1] The New England Journal of Medicine (2022). A Randomized Trial of Paxlovid in Adults at High Risk of Progression to severe COVID-19.

[2] The Journal of Clinical Pharmacology (2022). Cardiovascular Safety of Paxlovid in Patients with Severe Coronavirus Disease 2019.

[3] Adverse Event Reports: Pfizer’s Paxlovid COVID-19 treatment.

[4] U.S. Food and Drug Administration. (2022). Paxlovid: Prescribing Information.

[5] Drugs.com. (2022). Paxlovid Side Effects.

[6] Pfizer. (2022). ClinicalTrials.gov: Evaluation of the Safety and Efficacy of Paxlovid in Adults with COVID-19.

[7] DrugPatentWatch.com: Pfizer’s Paxlovid patent expiration and generic competition information.